BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26422655)

  • 1. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
    Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
    JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
    J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
    [No Abstract]   [Full Text] [Related]  

  • 3. Grade III hand-foot skin reaction induced by sorafenib.
    Chiriac A; Coros MF; Podoleanu C; Stolnicu S
    An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
    [No Abstract]   [Full Text] [Related]  

  • 4. Perforating folliculitis-like reaction related to sorafenib.
    Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
    Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed onset perforating folliculitis associated with sorafenib.
    Batalla A; Menéndez L; Blay P; Curto JR
    Australas J Dermatol; 2014 Aug; 55(3):233-5. PubMed ID: 25117168
    [No Abstract]   [Full Text] [Related]  

  • 6. [Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma].
    Shioya M; Nishimura T; Nishida A; Inatomi O; Bamba S; Sasaki M; Andoh A; Fujiyama Y
    Nihon Shokakibyo Gakkai Zasshi; 2014 Jul; 111(7):1424-32. PubMed ID: 24998734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
    Francini E; Bianco V
    Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
    Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
    Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
    Pichler M; Carriere C; Mazzoleni G; Kluge R; Eisendle K
    Clin Exp Dermatol; 2014 Mar; 39(2):232-3. PubMed ID: 24330088
    [No Abstract]   [Full Text] [Related]  

  • 11. Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature.
    Hamdeh S; Upadhyay S; Khanal N; Lanspa S
    J Gastrointest Cancer; 2016 Dec; 47(4):420-422. PubMed ID: 26223483
    [No Abstract]   [Full Text] [Related]  

  • 12. Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
    Ollech A; Stemmer SM; Merims S; Lotem M; Popovtzer A; Hendler D; Hodak E; Didkovsky E; Amitay-Laish I
    Int J Dermatol; 2016 Apr; 55(4):473-8. PubMed ID: 26825962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib-induced eruption resembling pityriasis rubra pilaris.
    Paz C; Querfeld C; Shea CR
    J Am Acad Dermatol; 2011 Aug; 65(2):452-453. PubMed ID: 21763585
    [No Abstract]   [Full Text] [Related]  

  • 14. Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
    Xu L; Wang B; Ding W
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e24-e25. PubMed ID: 28163072
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
    Kodaira M; Takahashi S; Takeuchi K; Yuasa T; Saotome T; Yonese J; Fukui I; Hatake K
    Ann Oncol; 2010 Jul; 21(7):1563-1565. PubMed ID: 20573851
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythema multiforme-like drug reaction to sorafenib.
    Lewin J; Farley-Loftus R; Pomeranz MK
    J Drugs Dermatol; 2011 Dec; 10(12):1462-3. PubMed ID: 22134572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
    Fathi AT; Lin WM; Durazzo T; Piris A; Sadrzadeh H; Bernardo L; Borger DR; McAfee SL; Kroshinsky D; Chen YB
    J Clin Oncol; 2016 Mar; 34(8):e70-2. PubMed ID: 25024084
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
    Chou JW; Cheng KS; Huang CW
    Intern Med; 2016; 55(6):623-7. PubMed ID: 26984079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifocal fixed drug eruption mimicking erythema multiforme.
    Sowden JM; Smith AG
    Clin Exp Dermatol; 1990 Sep; 15(5):387-8. PubMed ID: 2146052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML.
    Ernst J; Schäfer V; Rinke J; Wittig S; Beck JF; Ernst T; Gruhn B
    Ann Hematol; 2016 May; 95(6):1027-30. PubMed ID: 26979170
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.